Nuper, Iphase, in conjunction cum Perelman School of Medicine ad University of Pennsylvania, Co - Acta Antibody Antibody Antiqua (Si Cancer Morbi anti - Tlslp Monoclonal HZ - MCXXVII et probata eius affinitatem, specifica et facultatem inhibere TSLP.
Thymic stromal lymphopoietin (TSLP) est membrum estIl - II cytokineFamilia et Descyregulation TSLP - TSLP receptor (tslpr) via iam consociata cum progressionem allergic morbo etiam in late range de carcinomata, inter solidum et haematological tumores. Ideo propria binding of tslp usura antibodies est potential belli ad curatio allergic morbo et carcinomata. Et FDA currently approbat tezepepepumab, a Humanum anti - TSLP Monoclonal Antibody, quia curatio gravi asthma.
Iphase habet developed ad primum in hoc studium novum humanum anti - TSLP monoclonal, HZ - MCXXVII, cum eximia affinitate et specifica ad selectively ligare tslp cytokines. Comparari cum tezepepeab, in epitopes tenetur ad TSLP ab utroque sunt altus similes et HZ - MCXXVII habet fortior potentia ad angustos in commercium inter TSLP et TSLP. HZ - MCXXVII et ostendit superior effectus ad tezepepepumab in inhibendo TSLP - induci Stat5 activation et CCL17 et CCL22 Chemokine secretion.Hz - MCXXVII potest esse in potentia therapeutica agente ad allergic morbo et cancer.
Et Antibody Development technology involved in hoc studium et pertinet recombinant proteins et antibodias usus est in experimenta sunt provisum a Iphase.
Fig.1 Lepidium sativum de Monoclonal HZ - MCXXVII
Fig.2 inhibitionis TSLP - adductus ccl17 et CCL22 Chemokine secretio analyzed inPbmcs
Fig.3 schematic repraesentatione inhibitory effectus HZ - MCXXVII et Tezepepepiab in TSLP Signaling
Thymic stromal lymphopoietin (TSLP) est membrum estIl - II cytokineFamilia et Descyregulation TSLP - TSLP receptor (tslpr) via iam consociata cum progressionem allergic morbo etiam in late range de carcinomata, inter solidum et haematological tumores. Ideo propria binding of tslp usura antibodies est potential belli ad curatio allergic morbo et carcinomata. Et FDA currently approbat tezepepepumab, a Humanum anti - TSLP Monoclonal Antibody, quia curatio gravi asthma.
Iphase habet developed ad primum in hoc studium novum humanum anti - TSLP monoclonal, HZ - MCXXVII, cum eximia affinitate et specifica ad selectively ligare tslp cytokines. Comparari cum tezepepeab, in epitopes tenetur ad TSLP ab utroque sunt altus similes et HZ - MCXXVII habet fortior potentia ad angustos in commercium inter TSLP et TSLP. HZ - MCXXVII et ostendit superior effectus ad tezepepepumab in inhibendo TSLP - induci Stat5 activation et CCL17 et CCL22 Chemokine secretion.Hz - MCXXVII potest esse in potentia therapeutica agente ad allergic morbo et cancer.
Et Antibody Development technology involved in hoc studium et pertinet recombinant proteins et antibodias usus est in experimenta sunt provisum a Iphase.
Fig.1 Lepidium sativum de Monoclonal HZ - MCXXVII
Fig.2 inhibitionis TSLP - adductus ccl17 et CCL22 Chemokine secretio analyzed inPbmcs
Fig.3 schematic repraesentatione inhibitory effectus HZ - MCXXVII et Tezepepepiab in TSLP Signaling
Post tempus: MMXIV - VII - XXVII 16:34:37